# Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

> **NCT03196232** · PHASE2 · COMPLETED · sponsor: **George Albert Fisher** · enrollment: 3 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Gastric Carcinoma
- Stage IV Esophageal Cancer AJCC v7
- Stage IV Gastric Cancer AJCC v7
- Unresectable Esophageal Carcinoma

## Interventions

- **DRUG:** Epacadostat
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03196232
- **Lead sponsor:** George Albert Fisher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-13
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-05-29
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196232, "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03196232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*